These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 31973122)

  • 1. Computer-Aided Drug Design of β-Secretase, γ-Secretase and Anti-Tau Inhibitors for the Discovery of Novel Alzheimer's Therapeutics.
    Mouchlis VD; Melagraki G; Zacharia LC; Afantitis A
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31973122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease drug development based on Computer-Aided Drug Design.
    Zeng H; Wu X
    Eur J Med Chem; 2016 Oct; 121():851-863. PubMed ID: 26415837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spatiotemporal activation of the C/EBPβ/δ-secretase axis regulates the pathogenesis of Alzheimer's disease.
    Wang H; Liu X; Chen S; Ye K
    Proc Natl Acad Sci U S A; 2018 Dec; 115(52):E12427-E12434. PubMed ID: 30530690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease.
    Tomita T
    Adv Biol Regul; 2017 May; 64():33-38. PubMed ID: 28082052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's Disease and β-secretase Inhibition: An Update with a Focus on Computer-aided Inhibitor Design.
    Ugbaja SC; Lawal IA; Kumalo HM; Lawal MM
    Curr Drug Targets; 2022; 23(3):266-285. PubMed ID: 34370634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Studies on Design and Development of Drugs Against Alzheimer's Disease (AD) Based on Inhibition of BACE-1 and Other AD-causative Agents.
    Gupta SP; Patil VM
    Curr Top Med Chem; 2020; 20(13):1195-1213. PubMed ID: 32297584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenic mechanisms in Alzheimer's disease.
    Pastorino L; Lu KP
    Eur J Pharmacol; 2006 Sep; 545(1):29-38. PubMed ID: 16904664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study on the active mechanism of β-secretase inhibitors by molecular simulations.
    Tian YL; Lv M; Li JJ; Xu T; Zhai HL; Zhang XY
    Eur J Pharm Sci; 2015 Aug; 76():138-48. PubMed ID: 25965961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of glutaminyl cyclase ameliorates amyloid pathology in an animal model of Alzheimer's disease via the modulation of γ-secretase activity.
    Song H; Chang YJ; Moon M; Park SK; Tran PT; Hoang VH; Lee J; Mook-Jung I
    J Alzheimers Dis; 2015; 43(3):797-807. PubMed ID: 25114069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. γ-Secretase and its modulators: Twenty years and beyond.
    Xia W
    Neurosci Lett; 2019 May; 701():162-169. PubMed ID: 30763650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Traumatic brain injury triggers APP and Tau cleavage by delta-secretase, mediating Alzheimer's disease pathology.
    Wu Z; Wang ZH; Liu X; Zhang Z; Gu X; Yu SP; Keene CD; Cheng L; Ye K
    Prog Neurobiol; 2020 Feb; 185():101730. PubMed ID: 31778772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concatenation of molecular docking and molecular simulation of BACE-1, γ-secretase targeted ligands: in pursuit of Alzheimer's treatment.
    Jabir NR; Rehman MT; Alsolami K; Shakil S; Zughaibi TA; Alserihi RF; Khan MS; AlAjmi MF; Tabrez S
    Ann Med; 2021 Dec; 53(1):2332-2344. PubMed ID: 34889159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic Simulation, Docking and DFT Studies Applied to a Set of Anti-Acetylcholinesterase Inhibitors in the enzyme β-Secretase (BACE-1): An Important Therapeutic Target in Alzheimer`s disease.
    Silva-Junior EF; Barcellos Franca PH; Quintans-Junior LJ; Mendonca-Junior FJB; Scotti L; Scotti MT; de Aquino TM; de Araujo-Junior JX
    Curr Comput Aided Drug Des; 2017 Nov; 13(4):266-274. PubMed ID: 28382866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zileuton improves memory deficits, amyloid and tau pathology in a mouse model of Alzheimer's disease with plaques and tangles.
    Chu J; Li JG; Praticò D
    PLoS One; 2013; 8(8):e70991. PubMed ID: 23951061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Silico Design of Beta-Secretase Inhibitors in Alzheimer's Disease.
    Semighini EP
    Chem Biol Drug Des; 2015 Sep; 86(3):284-90. PubMed ID: 25476252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles.
    Chu J; Lauretti E; Craige CP; Praticò D
    J Alzheimers Dis; 2014; 41(3):729-37. PubMed ID: 24662099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. gamma-secretase as a therapeutic target for treatment of Alzheimer's disease.
    Tomita T; Iwatsubo T
    Curr Pharm Des; 2006; 12(6):661-70. PubMed ID: 16472155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.
    Scannevin RH; Chollate S; Brennan MS; Snodgrass-Belt PA; Peng H; Xu L; Jung MY; Bussiere T; Arastu MF; Talreja T; Xin Z; Dunstan RW; Fahrer D; Rohde E; Dunah AW; Wang J; Kumaravel G; Taveras AG; Moore Arnold H; Rhodes KJ
    Neuropharmacology; 2016 Apr; 103():57-68. PubMed ID: 26690893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.